Bayer's connection to China dates back to 1882. The company initially sold dyes in the Chinese market, and since then, the company's business in China has grown rapidly. Today, China has developed into one of Bayer's main centers for global investment.
At first, Bayer relied on the German trade bank and local trade organizations located at the trade port to introduce Bayer's products from sales centers to various provinces in China. Later, in 1913 and 1916, the first attempts to establish independent companies in Shanghai, "Firma Friedrich Bayer & Co." and "Bayer Pharmaceuticals Unlimited" were made. Bayer Pharma Unlimited also produces a range of products for China, including the famous aspirin® painkiller.
In 1986, Bayer established representative offices and liaison offices in Beijing and Shanghai, respectively.
In 1993, Bayer signed a comprehensive cooperation agreement with the former Ministry of Chemical Industry, which laid a solid foundation for Bayer to expand its business activities in China. A year later, Bayer (China) Co., Ltd. was established in Beijing as a holding company, mainly responsible for coordinating technology transfer and market development, and providing support for the preparation and implementation of joint venture projects. With the rapid development of the Chinese economy, gradual investment in a series of production facilities has followed.
In 2001, under the joint witness of former Chinese Premier Zhu Rongji, German Chancellor Schroeder, and former Bayer Board Chairman Dr. Schneider, Bayer officially broke ground on the construction of an integrated polymer base in the Shanghai Chemical Industry Park, marking Bayer's China's investment strategy has entered a new historical stage.
1882 Bayer enters China to start dye sales
1913 Bayer Trading Company is established in Shanghai
1936 Bayer Shanghai Pharmaceuticals begins production of "Aspirin"
1994 Bayer (China) Co., Ltd. was established as a holding company
1995-1997 Established 12 joint ventures designing various business subgroups; construction of Bayer Pharmaceutical Healthcare Plant started
2001 Construction of the Bayer Integrated Base in Shanghai begins
2001 Bayer CropScience's production base in Hangzhou begins production
2001 Signed a cooperative research agreement with the Chinese Academy of Sciences
2004 LANXESS spin-off
2005 Acquired Roche Consumer Health Products
Acquisition of Sagemel and Dongsheng (China) OTC business in 2008
Established global prescription drug R & D center in Beijing in 2009
Global headquarters of polycarbonate * business relocated to China in 2012
Bayer Pharma Healthcare's Beijing plant began expansion in 2014
Acquired Dianhong and Merck's OTC business in 2014
Covestro * spin-off and listing in 2015
The 100 million Euro injection of prescription medicine in Beijing was officially opened in 2016
Bayer completes acquisition of Monsanto in 2018 (acquisition completed on June 7)
* Former Bayer MaterialScience